Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Rapid vascular regrowth in tumors after reversal of VEGF inhibition.

Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, Yao VJ, Inai T, Brooks P, Freimark B, Shalinsky DR, Hu-Lowe DD, McDonald DM.

J Clin Invest. 2006 Oct;116(10):2610-21.

2.

Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.

Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, Hicklin DJ, Chaplin D, Foster FS, Benezra R, Kerbel RS.

Science. 2006 Sep 22;313(5794):1785-7.

3.

Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel.

Ng SS, Sparreboom A, Shaked Y, Lee C, Man S, Desai N, Soon-Shiong P, Figg WD, Kerbel RS.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4331-8.

4.

Predicting benefit from anti-angiogenic agents in malignancy.

Jubb AM, Oates AJ, Holden S, Koeppen H.

Nat Rev Cancer. 2006 Aug;6(8):626-35. Epub 2006 Jul 13. Review.

PMID:
16837971
5.

Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.

Tijink BM, Neri D, Leemans CR, Budde M, Dinkelborg LM, Stigter-van Walsum M, Zardi L, van Dongen GA.

J Nucl Med. 2006 Jul;47(7):1127-35.

6.

Antiangiogenesis drug design: multiple pathways targeting tumor vasculature.

Zhong H, Bowen JP.

Curr Med Chem. 2006;13(8):849-62. Review.

PMID:
16611071
7.

Pericytes limit tumor cell metastasis.

Xian X, Håkansson J, Ståhlberg A, Lindblom P, Betsholtz C, Gerhardt H, Semb H.

J Clin Invest. 2006 Mar;116(3):642-51. Epub 2006 Feb 9.

8.

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.

Casanovas O, Hicklin DJ, Bergers G, Hanahan D.

Cancer Cell. 2005 Oct;8(4):299-309.

9.

Absence of smooth muscle actin-positive pericyte coverage of tumor vessels correlates with hematogenous metastasis and prognosis of colorectal cancer patients.

Yonenaga Y, Mori A, Onodera H, Yasuda S, Oe H, Fujimoto A, Tachibana T, Imamura M.

Oncology. 2005;69(2):159-66. Epub 2005 Aug 24.

PMID:
16127287
10.

Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system.

Sengupta S, Eavarone D, Capila I, Zhao G, Watson N, Kiziltepe T, Sasisekharan R.

Nature. 2005 Jul 28;436(7050):568-72.

11.

Renal tubulointerstitial changes after internal irradiation with alpha-particle-emitting actinium daughters.

Jaggi JS, Seshan SV, McDevitt MR, LaPerle K, Sgouros G, Scheinberg DA.

J Am Soc Nephrol. 2005 Sep;16(9):2677-89. Epub 2005 Jun 29.

12.

Efforts to control the errant products of a targeted in vivo generator.

Jaggi JS, Kappel BJ, McDevitt MR, Sgouros G, Flombaum CD, Cabassa C, Scheinberg DA.

Cancer Res. 2005 Jun 1;65(11):4888-95.

13.

Identification of a transiently exposed VE-cadherin epitope that allows for specific targeting of an antibody to the tumor neovasculature.

May C, Doody JF, Abdullah R, Balderes P, Xu X, Chen CP, Zhu Z, Shapiro L, Kussie P, Hicklin DJ, Liao F, Bohlen P.

Blood. 2005 Jun 1;105(11):4337-44. Epub 2005 Feb 8.

14.

Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.

Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Munn LL, Jain RK.

Cancer Cell. 2004 Dec;6(6):553-63.

15.

Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2.

Miederer M, McDevitt MR, Borchardt P, Bergman I, Kramer K, Cheung NK, Scheinberg DA.

Clin Cancer Res. 2004 Oct 15;10(20):6985-92.

16.
17.

A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles.

Li L, Wartchow CA, Danthi SN, Shen Z, Dechene N, Pease J, Choi HS, Doede T, Chu P, Ning S, Lee DY, Bednarski MD, Knox SJ.

Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1215-27.

PMID:
15001266
18.

Vascular targeting agents as cancer therapeutics.

Thorpe PE.

Clin Cancer Res. 2004 Jan 15;10(2):415-27. Review.

19.

Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis.

Huang J, Soffer SZ, Kim ES, McCrudden KW, Huang J, New T, Manley CA, Middlesworth W, O'Toole K, Yamashiro DJ, Kandel JJ.

Mol Cancer Res. 2004 Jan;2(1):36-42.

20.

Targeted actinium-225 in vivo generators for therapy of ovarian cancer.

Borchardt PE, Yuan RR, Miederer M, McDevitt MR, Scheinberg DA.

Cancer Res. 2003 Aug 15;63(16):5084-90.

Items per page

Supplemental Content

Write to the Help Desk